BioSpace

Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict

With companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major backbone” of cancer treatment.

By BioSpace

1 min read
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights